BioCorteX Receives $5 Million Investment

BioCorteX, a UK-based digital medicine company, has raised $5 million in seed funding. BioCorteX's seed funding round was led by Sofinnova Partners and Hoxton Ventures. The funding will be used to further develop BioCorteX's Carbon Mirror platform, which provides insights into how drugs work in different microbiomes. As part of this financing round, Edward Kliphuis, Partner at Sofinnova Partners, and Hussein Kanji, Partner at Hoxton Ventures, joined the BioCorteX Board of Directors.

Also See: Startup Predicting Users’ Behavior: Quin AI

BioCorteX

The company, led by BioCorteX's Chief Executive Officer Dr. Nik Sharma and Chief Technology Officer Dr. Mo Alomari, is developing precision medicine solutions using in silico simulation to unravel the complex relationship bacteria, viruses and fungi play in health, disease and drug response. The company's pioneering product, Carbon Mirror™, uses technology that combines the principles of physics and chemistry to create highly accurate in silico simulations to assess and predict a person's response to treatment based on their microbiome profile.

BioCorteX's technology is a perfect example of how the power of data and new computational techniques can be used in healthcare. We have never fully understood the enormous complexity of the microbiome before, but Carbon Mirror™ gives us the power to illuminate cause-and-effect relationships. Edward Kliphuis, Partner at Sofinnova Partners, says that they can develop solutions that can greatly impact patient outcomes in the microbiome-host relationship. BiocorteX has built a microbiome database that it uses to train its AI and predict whether a drug candidate will be effective or can be customized for an individual.